Chia Tai Pharmaceutical (Qingdao) Co., Ltd.

Primary objective: To investigate the in vivo time course of ruxolitinib in healthy subjects after taking a single oral dose of ruxolitinib phosphate tablets (test preparation, specification: 20 mg, calculated as ruxolitinib) produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (licensed by Qingdao Guoxin Pharmaceutical Co., Ltd.) and ruxolitinib phosphate tablets (reference preparation, trade name: Jakavi®, specification: 20 mg, calculated as ruxolitinib) produced by Novartis Farmacéutica S.A. (licensed by Novartis Europharm Limited) in fasting and postprandial state using a randomized, open, two-period, two-sequence, double-crossover design, and to evaluate the bioequivalence between the preparations in fasting and postprandial state. Secondary objective: To evaluate the safety of the test preparation and reference preparation (trade name: Jakavi®) of ruxolitinib phosphate tablets in healthy subjects.

Main research purpose: To investigate the single oral administration of 0.5 μg test preparation idecalcidol soft capsule (specification: 0.5 μg/capsule, produced by Chia Tai Pharmaceutical (Qingdao) Co., Ltd.) and the reference preparation idecalcitol under fasting/postprandial conditions. Pharmacokinetic characteristics of Huachol Soft Capsule (trade name: EDIROL®, specification: 0.5 μg/capsule, produced by Chugai Seiko Co., Ltd.) in Chinese adult healthy subjects were evaluated after oral administration in fasting and postprandial states. Bioequivalence of formulations. Secondary study purpose: To evaluate the safety of a single oral dose of 0.5 μg of the test preparation and reference preparation in Chinese adult healthy subjects under fasting/postprandial conditions.

Main research purposes: Examine the single oral administration of 0.75 μg of the test preparation idecalcitol soft capsule (specification: 0.75 μg/capsule, produced by Chia Tai Pharmaceutical (Qingdao) Co., Ltd.) and the reference preparation idecalcitol soft capsule under fasting/postprandial conditions. (Trade name: EDIROL®, specification: 0.75μg/tablet, manufactured by Chugai Seiko Co., Ltd.) Pharmacokinetic characteristics in Chinese adult healthy subjects, and evaluation of the bioequivalence of the two preparations taken orally in the fasting and postprandial states effectiveness. Secondary research purpose: To evaluate the safety of a single oral dose of 0.75 μg of the test preparation and reference preparation in Chinese adult healthy subjects under fasting/postprandial conditions.